Use of product listing agreements by Canadian provincial drug benefit plans
The use of confidential negotiated agreements between pharmaceutical manufacturers and drug plans that support reimbursement of some products has emerged as a global pricing tool, with associated benefits and drawbacks. This study looks at the frequency of contract use by provincial drug benefit plans and makes recommendations for moving forward within this pricing paradigm.

Steve Morgan
Irfan Dhalla
Barbara Mintzes
Joel Lexchin
Ingrid S. Sketris